First patient treated in Airiver Medical’s RESTORE-2 trial for CRS

Airiver Medical has treated the first patient in its RESTORE-2 pivotal clinical trial assessing the ESSpand Sinus DCB for CRS. The study is enrolling up to 300 US patients with CRS to evaluate the ESSpand DCB with endoscopic sinus surgery. CRS is defined as inflammation of the nose and paranasal sinuses persisting for at least three months despite intervention. Credit: JHVEPhoto / Shutterstock.com. Airiver Medical has treated the first patient in its RESTORE-2 pivotal clinical trial assessing the ESSpand Sinus drug-coated balloon (DCB) for chronic rhinosinusitis (CRS). The treatment took place at Advanced ENT and Allergy in Louisville, Kentucky, US,…

Source: Medical Device Network